550 related articles for article (PubMed ID: 29184552)
21. CD39/CD73/A2AR pathway and cancer immunotherapy.
Xia C; Yin S; To KKW; Fu L
Mol Cancer; 2023 Mar; 22(1):44. PubMed ID: 36859386
[TBL] [Abstract][Full Text] [Related]
22. Murine and Human-Purified very Small Embryonic-like Stem Cells (VSELs) Express Purinergic Receptors and Migrate to Extracellular ATP Gradient.
Bujko K; Brzezniakiewicz-Janus K; Jarczak J; Kucia M; Ratajczak MZ
Stem Cell Rev Rep; 2024 Apr; ():. PubMed ID: 38635127
[TBL] [Abstract][Full Text] [Related]
23. Emerging roles of purinergic signaling in anti-cancer therapy resistance.
Zanoni M; Pegoraro A; Adinolfi E; De Marchi E
Front Cell Dev Biol; 2022; 10():1006384. PubMed ID: 36200041
[TBL] [Abstract][Full Text] [Related]
24. Hyperthermia and associated changes in membrane fluidity potentiate P2X7 activation to promote tumor cell death.
de Andrade Mello P; Bian S; Savio LEB; Zhang H; Zhang J; Junger W; Wink MR; Lenz G; Buffon A; Wu Y; Robson SC
Oncotarget; 2017 Sep; 8(40):67254-67268. PubMed ID: 28978031
[TBL] [Abstract][Full Text] [Related]
25. Divergent regulatory roles of extracellular ATP in the degranulation response of mouse bone marrow-derived mast cells.
Yoshida K; Ito M; Matsuoka I
Int Immunopharmacol; 2017 Feb; 43():99-107. PubMed ID: 27988461
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.
Bastid J; Regairaz A; Bonnefoy N; Déjou C; Giustiniani J; Laheurte C; Cochaud S; Laprevotte E; Funck-Brentano E; Hemon P; Gros L; Bec N; Larroque C; Alberici G; Bensussan A; Eliaou JF
Cancer Immunol Res; 2015 Mar; 3(3):254-65. PubMed ID: 25403716
[TBL] [Abstract][Full Text] [Related]
27. Purinergic signaling in B cells.
Przybyła T; Sakowicz-Burkiewicz M; Pawełczyk T
Acta Biochim Pol; 2018; 65(1):1-7. PubMed ID: 29360885
[TBL] [Abstract][Full Text] [Related]
28. Nanobody-Based Biologics for Modulating Purinergic Signaling in Inflammation and Immunity.
Menzel S; Schwarz N; Haag F; Koch-Nolte F
Front Pharmacol; 2018; 9():266. PubMed ID: 29636685
[TBL] [Abstract][Full Text] [Related]
29. The interplay between the DNA damage response and ectonucleotidases modulates tumor response to therapy.
Stagg J; Golden E; Wennerberg E; Demaria S
Sci Immunol; 2023 Jul; 8(85):eabq3015. PubMed ID: 37418547
[TBL] [Abstract][Full Text] [Related]
30. Purinergic enzymes on extracellular vesicles: immune modulation on the go.
Winzer R; Nguyen DH; Schoppmeier F; Cortesi F; Gagliani N; Tolosa E
Front Immunol; 2024; 15():1362996. PubMed ID: 38426088
[TBL] [Abstract][Full Text] [Related]
31. Dysfunctional purinergic signaling correlates with disease severity in COVID-19 patients.
Pietrobon AJ; Andrejew R; Custódio RWA; Oliveira LM; Scholl JN; Teixeira FME; de Brito CA; Glaser T; Kazmierski J; Goffinet C; Turdo AC; Yendo T; Aoki V; Figueiró F; Battastini AM; Ulrich H; Benard G; Duarte AJDS; Sato MN
Front Immunol; 2022; 13():1012027. PubMed ID: 36248842
[TBL] [Abstract][Full Text] [Related]
32. Altered purinergic signaling in the tumor associated immunologic microenvironment in metastasized non-small-cell lung cancer.
Schmid S; Kübler M; Korcan Ayata C; Lazar Z; Haager B; Hoßfeld M; Meyer A; Cicko S; Elze M; Wiesemann S; Zissel G; Passlick B; Idzko M
Lung Cancer; 2015 Dec; 90(3):516-21. PubMed ID: 26505137
[TBL] [Abstract][Full Text] [Related]
33. Extracellular adenosine triphosphate and adenosine in cancer.
Stagg J; Smyth MJ
Oncogene; 2010 Sep; 29(39):5346-58. PubMed ID: 20661219
[TBL] [Abstract][Full Text] [Related]
34. Aberrant Adenosine Triphosphate Release and Impairment of P2Y2-Mediated Signaling in Sarcoglycanopathies.
Benzi A; Baratto S; Astigiano C; Sturla L; Panicucci C; Mamchaoui K; Raffaghello L; Bruzzone S; Gazzerro E; Bruno C
Lab Invest; 2023 Mar; 103(3):100037. PubMed ID: 36925196
[TBL] [Abstract][Full Text] [Related]
35. The P2X7 Receptor in Oncogenesis and Metastatic Dissemination: New Insights on Vesicular Release and Adenosinergic Crosstalk.
Adinolfi E; De Marchi E; Grignolo M; Szymczak B; Pegoraro A
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762206
[TBL] [Abstract][Full Text] [Related]
36. Host CD39 Deficiency Affects Radiation-Induced Tumor Growth Delay and Aggravates Radiation-Induced Normal Tissue Toxicity.
Meyer AV; Klein D; de Leve S; Szymonowicz K; Stuschke M; Robson SC; Jendrossek V; Wirsdörfer F
Front Oncol; 2020; 10():554883. PubMed ID: 33194619
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic potency of pharmacological adenosine receptors agonist/antagonist on cancer cell apoptosis in tumor microenvironment, current status, and perspectives.
Soleimani A; Bahreyni A; Roshan MK; Soltani A; Ryzhikov M; Shafiee M; Soukhtanloo M; Jaafari MR; Mashkani B; Hassanian SM
J Cell Physiol; 2019 Mar; 234(3):2329-2336. PubMed ID: 30191994
[TBL] [Abstract][Full Text] [Related]
38. Purinergic signaling: Diverse effects and therapeutic potential in cancer.
Kaur J; Dora S
Front Oncol; 2023; 13():1058371. PubMed ID: 36741002
[TBL] [Abstract][Full Text] [Related]
39. Purinergic signalling links mechanical breath profile and alveolar mechanics with the pro-inflammatory innate immune response causing ventilation-induced lung injury.
Hasan D; Blankman P; Nieman GF
Purinergic Signal; 2017 Sep; 13(3):363-386. PubMed ID: 28547381
[TBL] [Abstract][Full Text] [Related]
40. Istradefylline induces A2A/P2X7 crosstalk expression inducing pro-inflammatory signal, and reduces AKT/mTOR signaling in melanoma-bearing mice.
Gutknecht da Silva JL; Passos DF; Cabral FL; Miron VV; Schetinger MRC; Cardoso AA; Dal Piva CH; Gomes CO; Ebone RS; Leal DBR
Med Oncol; 2023 May; 40(6):178. PubMed ID: 37188995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
